For decades, omega-3 fatty acids were described as “anti-inflammatory” — a vague label suggesting they simply blunt prostaglandin production or dilute arachidonic acid in cell membranes. That model is now obsolete. Beginning in the early 2000s, Charles Serhan’s laboratory at Harvard discovered that EPA and DHA are enzymatically converted into a family of potent lipid mediators — resolvins, protectins, and maresins — that do not suppress inflammation. They actively end it. This represents a paradigm shift: inflammation resolution is not a passive decay but a programmed, agonist-driven process orchestrated by specialized pro-resolving mediators (SPMs).[1]
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators are endogenous lipid autacoids biosynthesized from omega-3 polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a smaller contribution from docosapentaenoic acid (DPA). They fall into three principal families. Resolvins are derived from EPA (E-series resolvins, including RvE1, RvE2, RvE3) and DHA (D-series resolvins, including RvD1 through RvD6). Protectins (also called neuroprotectins when produced in neural tissue) include PD1/NPD1 and are derived exclusively from DHA. Maresins (macrophage mediators in resolving inflammation) — including MaR1 and MaR2 — are also DHA-derived and are produced predominantly by macrophages during the resolution phase.[1][2]
Unlike classical eicosanoids such as prostaglandin E2 or leukotriene B4 — which drive the initiation of inflammation — SPMs are produced during a programmed lipid mediator class switch that occurs as inflammation transitions from initiation to resolution. They act in the picogram to nanogram range through specific G protein–coupled receptors, including ChemR23/ERV1 (RvE1), GPR32/DRV1 and ALX/FPR2 (RvD1), and LGR6 (MaR1).[2]
How SPMs Work
Lipid Mediator Class Switching: During acute inflammation, prostaglandin E2 and prostaglandin D2 — initially pro-inflammatory — paradoxically induce the enzymatic machinery (15-lipoxygenase) required to synthesize SPMs from EPA and DHA. This temporal switch transforms the lipid mediator profile from pro-inflammatory to pro-resolving without any external signal, embedding resolution within the inflammatory program itself.[1]
Active Termination, Not Suppression: Classical anti-inflammatory drugs (NSAIDs, corticosteroids) inhibit the synthesis of pro-inflammatory mediators. SPMs operate through a fundamentally different mechanism: they are agonists that bind specific receptors on neutrophils, macrophages, and other immune cells to actively trigger resolution programs. This includes halting neutrophil infiltration, stimulating non-phlogistic recruitment of monocytes, and enhancing macrophage efferocytosis — the clearance of apoptotic cells and cellular debris.[2][3]
Efferocytosis Enhancement: One of the defining actions of SPMs is potentiation of efferocytosis. RvD1, RvE1, PD1, and MaR1 each increase the capacity of macrophages to engulf apoptotic neutrophils, which is critical for resolving inflammation without tissue damage. Failure of efferocytosis is now recognized as a central feature of chronic inflammatory diseases including atherosclerosis, COPD, and inflammatory bowel disease.[3]
Tissue Regeneration: Beyond resolving inflammation, SPMs — particularly MaR1 — stimulate tissue repair and regeneration. Maresin 1 was shown to accelerate planarian tissue regeneration and promote wound healing in mammalian models, suggesting these mediators function not only to end inflammation but to restore tissue homeostasis.[4]
Clinical Evidence
Cardiovascular Disease: Plasma SPM levels are reduced in patients with established cardiovascular disease and peripheral artery disease compared with healthy controls. In atherosclerotic plaques, an imbalance between pro-inflammatory leukotriene B4 and pro-resolving RvD1 correlates with plaque vulnerability and progression. This has reframed the high-dose EPA findings from REDUCE-IT (icosapent ethyl, 4 g/day) — the cardiovascular benefit may reflect not just lipid lowering or membrane effects, but increased substrate availability for resolvin biosynthesis.[5]
Inflammatory Pain: Resolvins have demonstrated potent analgesic effects in preclinical models of inflammatory and neuropathic pain. RvE1 and RvD1 reduce TRPV1- and TRPA1-mediated nociception at doses orders of magnitude lower than conventional analgesics, suggesting a novel non-opioid mechanism for pain resolution that operates through endogenous resolution circuits rather than receptor blockade.[2]
Neurodegeneration and Alzheimer’s Disease: Neuroprotectin D1 (NPD1) is biosynthesized in the retina and brain from DHA. Postmortem studies have found NPD1 levels markedly reduced in the hippocampi of patients with Alzheimer’s disease, and NPD1 has been shown to downregulate amyloid-β42 generation and protect neurons from oxidative stress in cellular models.[4]
Sepsis and Acute Inflammation: In murine models of sepsis, administration of RvD1, RvD2, and protectins improves survival, accelerates bacterial clearance, and reduces organ injury — even when given after the onset of inflammation. These findings have prompted ongoing translational work evaluating SPM analogs as potential therapeutics for acute respiratory distress syndrome and systemic inflammatory conditions.[3]
Safety Profile
SPMs themselves are endogenous human lipid mediators — they are not foreign compounds. Their natural ligands act in the picomolar to nanomolar range and are rapidly metabolized, limiting systemic exposure. To date, no synthetic SPM has been approved by the FDA, though stable analogs (e.g., benzo-RvE1, 17R-RvD1) are in preclinical and early translational development.
Clinically, the safety conversation centers on omega-3 fatty acid supplementation as substrate. EPA and DHA at doses up to 4 g/day (as in REDUCE-IT) are generally well tolerated. The most consistently reported adverse signal at high doses is an increased incidence of atrial fibrillation, observed across REDUCE-IT, STRENGTH, and OMEMI trials. Bleeding risk, historically a concern, has not materialized as clinically significant in large randomized trials. Gastrointestinal symptoms (eructation, dyspepsia) are common but mild.
Importantly, supplementing EPA and DHA does not guarantee elevated SPM production. The biosynthetic enzymes — 5-LOX, 12-LOX, and 15-LOX — must be appropriately expressed and active. Genetic polymorphisms in ALOX5 and ALOX15, as well as concurrent NSAID or aspirin use, alter the SPM profile. Low-dose aspirin notably triggers the production of “aspirin-triggered” epimeric SPMs (17R-resolvins, AT-LXA4) that are more resistant to enzymatic degradation than their native counterparts.[2]
SPMs vs Classical Anti-Inflammatory Approaches
NSAIDs: Cyclooxygenase inhibition blocks both pro-inflammatory prostaglandins and the prostaglandin-driven lipid mediator class switch that initiates SPM biosynthesis. This may explain why chronic NSAID use is associated with delayed wound healing, impaired fracture repair, and persistent low-grade inflammation despite symptom relief. SPMs, by contrast, allow inflammation to proceed normally and then terminate it on schedule.[1]
Corticosteroids: Glucocorticoids broadly suppress immune function and can impair both pathogen clearance and efferocytosis. They are immunosuppressive rather than pro-resolving. Interestingly, some of the anti-inflammatory effects of glucocorticoids are now thought to involve upregulation of annexin A1 — a peptide that signals through the same ALX/FPR2 receptor as RvD1 — partially overlapping with endogenous resolution pathways.
Omega-3 Supplementation Alone: Standard fish oil provides EPA and DHA as substrate, but the conversion to bioactive SPMs depends on enzymatic capacity, inflammatory state, and aspirin/NSAID exposure. This may explain heterogeneous clinical results across omega-3 trials: patients with intact resolution machinery benefit more than those whose pathways are blocked or downregulated. Direct measurement of plasma SPM levels — increasingly available through targeted lipidomics — may become a more meaningful biomarker than EPA/DHA red blood cell content alone.[5]
Resolution Pharmacology: The emerging field of resolution pharmacology aims to develop stable SPM analogs and small-molecule agonists of ALX/FPR2, ChemR23, and GPR32. Unlike immunosuppressants, these agents would activate endogenous resolution programs — terminating inflammation without compromising host defense. Several candidates are in preclinical development for periodontitis, inflammatory bowel disease, and chronic wound healing.[4]
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Chiang N, Dalli J. “The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution.” Seminars in Immunology. 2015;27(3):200-215.
- Spite M, Clària J, Serhan CN. “Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.” Cell Metabolism. 2014;19(1):21-36.
- Serhan CN, Yang R, Martinod K, et al. “Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.” Journal of Experimental Medicine. 2009;206(1):15-23.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
